Calling All ALLR Investors: The Allegations Unveiled
Bensalem, Pennsylvania – September 26, 2024 — Investors with substantial losses in Allarity Therapeutics, Inc. (“Allarity” or the “Company”) have an opportunity to take the lead in a securities fraud class action lawsuit.
The class period under scrutiny is from May 17, 2022, to July 19, 2024, with a lead plaintiff deadline of November 12, 2024. The Law Offices of Howard G. Smith are urging affected investors to get in touch to discuss their legal rights in this lawsuit.
During this period, the complaint alleges that the defendants failed to disclose crucial information to investors. The allegations include overstating the Dovitinib NDA’s regulatory prospects, engaging in illicit conduct related to the Dovitinib NDA and Dovitinib-DRP PMA, and downplaying the risks of regulatory and legal actions related to these matters. As a result, the positive statements made by the defendants regarding the Company’s business and prospects were deemed misleading.
Opportunities for Investors
Investors who suffered losses on their Allarity investments are advised to contact Howard G. Smith’s Law Offices to explore their options. The lawsuit provides an opportunity for affected investors to participate without requiring immediate action. It is also possible to seek independent legal counsel or stay as an absent member of the class action.
Legal Counsel and Contact Information
For those seeking more information on the class action lawsuit or with any related queries, Howard G. Smith, Esquire, can be reached at 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by phone at (215) 638-4847, or via email at howardsmith@howardsmithlaw.com. Additional details are available on the Law Offices of Howard G. Smith’s website.
Note: This press release may contain Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.
Original content:Click here
SOURCE: Law Offices of Howard G. Smith
